(NASDAQ:SLNO) NEW YORK, Sept. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The...
Related Questions
How might the lawsuit investigation affect Soleno Therapeutics' short‑term stock volatility and trading volume?
What potential financial exposure or settlement costs could arise from the claims, and how will that impact the company’s balance sheet and earnings outlook?
Are there any precedent cases in the biotech sector where similar investor lawsuits led to regulatory scrutiny or product development delays?